Education and Training
Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome
Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Transvaginal botulinum toxin A (BTA) injection
Eligibility
Inclusion Criteria:
- Females with IC/BPS
- Females who are considering intradetrusor BTA chemodenervation for the treatment of
refractory IC/BPS
Exclusion Criteria:
- Involvement in other studies with potentially overlapping indications or symptoms
- Patients who are unable to undergo a transvaginal intervention as a result of anatomic
barriers or discomfort will be excluded from enrollment
- patients known to be pregnant or breastfeeding
- Known allergy to BTA injection therapy or lidocaine
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amy D. Dobberfuhl, M.D.
650-723-3391
Not Recruiting